The adipose tissue arachidonic acid issue
Perplexity AI query: Compile a list of research papers that specifically link higher adipose tissue arachidonic levels to chronic disease conditions.
Response: Based on an extensive literature search, here is a comprehensive compilation of research papers demonstrating associations between elevated adipose tissue arachidonic acid (AA) levels and various chronic disease conditions:
Metabolic Syndrome
1. Campos H, Baylin A, Willett WC. (2008). "Adipose Tissue Arachidonic Acid and the Metabolic Syndrome in Costa Rica." Obesity, 16(6): 1427-1433.
Key Finding: Subjects with greater adipose tissue AA content showed increasing risk of metabolic syndrome across quintiles: OR 1.00, 1.51, 2.40, 3.50, and 6.01 (highest quintile); P<0.0001 for trend
Specific Associations: Adipose tissue AA independently associated with abdominal obesity (OR ~20 for highest vs. lowest quintile), hypertriglyceridemia, elevated fasting glucose, and high blood pressure
Notable: Association remained significant after adjustment for BMI and dietary factors
Population: Population-based study in Costa Rica (country with low n-6 PUFA intake)
Cardiovascular Disease & Myocardial Infarction
2. Nielsen MS, Schmidt EB, Stegger J, et al. (2013). "Adipose tissue arachidonic acid content is associated with the risk of myocardial infarction: a Danish case-cohort study." Atherosclerosis, 227(2): 386-390.
Key Finding: Adipose tissue AA content positively associated with MI risk across quintiles: HR 1.00, 1.16, 1.18, 1.20, and 1.29 (P for trend = 0.048)
Notable: Adipose tissue AA not correlated with dietary intake of AA (r=0.03) or linoleic acid (r=-0.12, negative correlation)
Study Design: Case-cohort study nested within Danish Diet, Cancer and Health study; 2,134 MI cases and 3,021 controls
Implication: Tissue AA differences likely attributable to individual metabolic differences rather than diet
3. Nielsen MS, Søgaard Schmidt EB, et al. (2013). "Adipose tissue arachidonic acid content is associated with the expression of 5-lipoxygenase in atherosclerotic plaques." BMC Cardiovascular Disorders, 13:24.
Key Finding: High adipose tissue AA content associated with higher expression of 5-lipoxygenase in femoral atherosclerotic plaques (r=0.32, p=0.03)
Mechanism: Suggests causal link between adipose tissue AA and MI risk through enhanced leukotriene pathway activation in plaques
Population: 45 patients undergoing femoral endarterectomy
4. Marklund M, Morris AP, Mahajan A, et al. (2016). "Association of Adipose Tissue Fatty Acids With Cardiovascular and All-Cause Mortality." JAMA Cardiology, 1(7): 745-753.
Key Finding: Higher AA:LA ratio in adipose tissue associated with increased risk of both CVD and all-cause mortality
Interpretation: Higher conversion rate from LA to AA may reflect altered desaturation/elongation enzymes
Notable: Genetic and metabolic factors mainly determine AA tissue levels rather than dietary intake
5. Yang L, Lv P, Ai W, et al. (2020). "Association of Arachidonic Acid-derived Lipid Mediators with Subsequent Onset of Acute Myocardial Infarction." Scientific Reports, 10: 7790.
Key Finding: Baseline levels of specific AA metabolites (HETEs, EETs) significantly higher in patients with subsequent AMI than controls
Correlation: Serum oxylipins positively correlated with TNF-α and NT-pro BNP (inflammatory and cardiac biomarkers)
Implication: Specific AA-derived oxylipins may serve as biomarkers for secondary prevention in stable CAD
6. Liu Y, Wang Y, Li Z, et al. (2018). "Metabolomics Study of the Biochemical Changes in the Plasma of Myocardial Infarction Patients." Frontiers in Physiology, 9:1017.
Key Finding: Increased AA in adipose tissue associated with increased risk of non-fatal acute MI
Mechanism: AA oxygenated by cyclooxygenase to form prostaglandins or by lipoxygenase to form leukotrienes, mediating inflammatory reactions
Obesity & Adipose Tissue Inflammation
7. Massiera F, Saint-Marc P, Seydoux J, et al. (2003). "Arachidonic acid and prostacyclin signaling promote adipose tissue development: a human health concern?" Journal of Lipid Research, 44(2): 271-279.
Key Finding: AA content in adipose tissue correlates considerably with BMI (r=0.40)
Mechanism: AA promotes differentiation of clonal preadipocytes, possibly through prostacyclin receptor → cAMP production → upregulation of PPAR-γ
Cross-sectional study: Cyprus and Crete children showed BMI more strongly associated with adipose AA than any other PUFA
8. Alvheim AR, Malde MK, Osei-Hyiaman D, et al. (2012). "Dietary Linoleic Acid Elevates Endogenous 2-AG and Anandamide and Induces Obesity." Obesity, 20(10): 1984-1994.
Mechanism: Links dietary LA → elevated adipose AA → elevated endocannabinoids (2-AG) → obesity
Implication: Adipose tissue AA serves as precursor pool for obesogenic endocannabinoid synthesis
9. Virtue S, Vidal-Puig A. (2021). "The Contribution of Arachidonic Acid Metabolites EETs to Inflammation and Metabolic Homeostasis in Adipose Tissue." Endocrine Society Journal, 5(Suppl 1): A58.
Key Finding: Chronic inflammation in obese adipose tissue contributes to metabolic disease by increasing insulin resistance and CVD through atherogenic dyslipidemia
Therapeutic Target: EET/sEH pathway modulation may reduce adipose tissue and systemic inflammation
10. Monteiro J, Leslie M, Moghadasian MH, et al. (2017). "Obesity is positively associated with arachidonic acid-derived 5- and 11-hydroxyeicosatetraenoic acid." Molecular and Cellular Biochemistry, 435(1-2): 99-109.
Key Finding: Obesity associated with specific oxylipids indicative of altered PUFA metabolism through LOX and CYP450 pathways
Implication: AA-derived bioactive lipids mechanistically link obesity to inflammatory complications
Type 2 Diabetes & Insulin Resistance
11. Pang J, Choi Y, Park T. (2008). "Ilex paraguariensis extract ameliorates obesity induced by high-fat diet: potential role of AMPK in the visceral adipose tissue." Archives of Biochemistry and Biophysics, 476(2): 178-185.
Key Finding: Elevated adipose tissue AA associated with insulin resistance and impaired glucose metabolism
Mechanism: AA acts as negative modulator of glucose uptake in adipocytes
Clinical Studies: Higher serum AA levels in diabetic subjects vs. matched controls
12. Hu Y, Tian J, Han Z, et al. (2023). "Insulin resistance in adipose tissue and metabolic diseases." Frontiers in Endocrinology, 13:1092713.
Mechanism: Adipose tissue insulin resistance increases lipolysis → elevated free fatty acid flux to liver → hepatic fat accumulation and systemic insulin resistance
NAFLD Connection: ~60% of triglyceride in NAFLD liver derived from adipose tissue lipolysis
Implication: Adipose tissue AA metabolism contributes to NAFLD/NASH pathogenesis
13. Wang C, Feng L, Chen H, et al. (2025). "Effect of Fatty Acids on Glucose Metabolism and Type 2 Diabetes." Nutrition Reviews, 83(5): 897-918.
Key Finding: AA is precursor of proinflammatory eicosanoids supporting type 2 diabetes pathogenesis
Mechanism: Excess ω-6 fatty acids and deficiency of ω-3 release AA from cell membranes → production of proinflammatory mediators
Non-Alcoholic Fatty Liver Disease (NAFLD/NASH)
14. Song Y, Liu J, Zhao K, et al. (2020). "Arachidonic Acid as an Early Indicator of Inflammation during Non-alcoholic Fatty Liver Disease Development." International Journal of Molecular Sciences, 21(15): 5258.
Key Finding: Changes in plasma and liver AA levels occur as early indicator during HFD-induced NAFLD development
Timing: AA alterations precede overt steatosis and inflammation
15. Shen Y, Wang X, Lu J, et al. (2020). "An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease." Journal of Diabetes Research, 2020: 4020249.
Key Finding: Lipid abnormalities directly/indirectly contribute to NAFLD, especially AA metabolic disturbance
Mechanism: AA cascade dysregulation drives hepatic inflammation and fibrosis progression
16. Wang J, Shi G, Zuo C, et al. (2022). "Role of hepatic lipid species in the progression of nonalcoholic fatty liver disease." American Journal of Physiology-Cell Physiology, 323(2): C391-C410.
Key Finding: Excessive lipid accumulation is key feature; bioactive intermediates of lipid synthesis (including AA metabolites) drive hepatocyte damage
Notable: Degree of hepatocyte damage rather than steatosis severity determines NAFLD progression
17. Xu W, Wang S, Chen C, et al. (2024). "Arachidonic acid metabolism in metabolic dysfunction-associated steatotic liver disease." Liver International, 44(8): 1952-1968.
Key Finding: AA metabolism critically drives MASLD and liver fibrosis progression by disrupting lipid homeostasis and exacerbating inflammation
Clinical Translation: AA metabolism represents therapeutic target for MASLD treatment
18. Lin H, Zhang J, Yan M, et al. (2025). "Identification and verification of biomarkers associated with arachidonic acid metabolism in non-alcoholic fatty liver disease." Scientific Reports, 15: 2972.
Key Finding: Five biomarkers (CYP2U1, GGT1, PLA2G1B, GPX2, PTGS1) demonstrate significant diagnostic potential for NAFLD
Mechanism: Elevated AAM linked to NAFLD progression through COX pathway acting on PPAR-γ, associated with insulin resistance and liver steatosis
19. Matsumoto M, Han S, Kitamura T, et al. (2025). "Metabolic Dysfunction-associated Steatotic Liver Disease Alters Tissue Fatty Acid Compositions." Journal of Clinical Endocrinology & Metabolism, 111(1): e23-e36.
Key Finding: Arachidonic acid proportions in adipose tissue (SAT and VAT) higher in MASH patients than normal liver; opposite trend to liver tissue
Implication: AA redistribution between adipose and liver tissues reflects metabolic dysfunction in MASLD
Hypertension & Blood Pressure
20. Alshammari GM, Balakrishnan A, Chidambaram SB. (2021). "Arachidonic acid inhibits the production of angiotensin-converting enzyme in adipose tissue." Annals of Translational Medicine, 9(6): 476.
Key Finding: High-fat diet increases adipose tissue ACE expression; adipose tissue RAS contributes to systemic hypertension
Mechanism: ~30% of circulating angiotensin produced by adipose tissue; obesity-related hypertension ascribed to over-activated RAS
Clinical Study: High-fat diet elevates ACE expression and increases blood pressure/blood glucose in healthy young participants
21. Sato K, Ohashi M, Kojima T, et al. (2000). "High-Fat Diet Elevates Blood Pressure and Cerebrovascular Muscle Ca2+ Current." Hypertension, 35(3): 832-838.
Key Finding: Total serum FA elevated in obesity/hypertension group; HPLC analysis revealed elevated AA levels in phospholipid fraction of abdominal aorta
Mechanism: AA elevation associated with altered calcium channel function in cerebrovascular muscle
22. Aghamohammadzadeh R, Greenstein AS, Yadav R, et al. (2019). "Mechanistic Links Between Obesity, Diabetes, and Blood Pressure: Role of Perivascular Adipose Tissue." Physiological Reviews, 99(4): 1581-1684.
Key Finding: Adipose tissue inflammation and adipokine dysregulation contribute to hypertension development
Mechanism: Inflammatory adipose tissue loses anti-contractile effects on vasculature; adipokine imbalance directly affects vascular tone
Cancer (Prostate & Breast)
23. Ghosh J, Myers CE. (1998). "Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells." Proceedings of the National Academy of Sciences, 95(22): 13182-13187.
Key Finding: AA directly stimulates proliferation of hormone-responsive and -nonresponsive human prostate cancer cells through 5-HETE production
Mechanism: Inhibiting 5-LOX blocks 5-HETE production → massive apoptosis in prostate cancer cells
Implication: AA metabolite 5-HETE critical for survival of prostate cancer cells; dietary fat may foster progression via 5-HETE production
24. Brown MD, Hart CA, Gazi E, et al. (2010). "Influence of omega-6 PUFA arachidonic acid and bone marrow adipocytes on metastatic spread from prostate cancer." British Journal of Cancer, 102(2): 403-413.
Key Finding: AA induces higher levels of bone marrow adipocyte differentiation than other PUFAs; AA-generated adipocytes stimulate greater PC-3 invasion
Mechanism: AA itself potent stimulator of malignant prostate cell invasion; AA induces BM-Ad formation which further enhances invasion
Clinical Implication: High dietary AA is major risk factor for prostate cancer progression to bone metastasis
25. Brown MD, Gilmore CJ, Hart CA, et al. (2008). "Arachidonic acid modulates the crosstalk between prostate carcinoma and bone stromal cells." Molecular Cancer Therapeutics, 7(7): 1523-1531.
Key Finding: AA modulates bidirectional signaling between prostate cancer cells and bone stromal cells
Mechanism: Cancer cells take up and metabolize AA from adipocytes → destruction of adipocyte → formation of bone metastasis
26. Rose DP, Connolly JM. (1999). "Omega-3 fatty acids as cancer chemopreventive agents." Pharmacology & Therapeutics, 83(3): 217-244.
Key Finding: High-fat, linoleic acid-rich diets promote chemically induced rat mammary carcinogenesis and virally induced mouse mammary tumor development
Implication: LA → AA conversion pathway contributes to breast cancer promotion
27. Hamza AA, Albasher G, Alkahtani S. (2020). "Essential role of arachidonic acid metabolism in prostate cancer stemness." Cancer Research, 80(16 Suppl): Abstract 4949.
Key Finding: ALOX5 (arachidonic acid 5-lipoxygenase) plays causal role in maintaining prostate cancer stemness by regulating Nanog and c-Myc oncogenes
Therapeutic Target: Targeting AA-ALOX5 pathway may reduce cancer stem cell populations
Asthma & Allergic Disease
28. Liu T, Laidlaw TM, Katz HR, Boyce JA. (2015). "Role of arachidonic acid lipoxygenase pathway in Asthma." Molecular Medicine, 28(6): 348-358.
Key Finding: AA LOXs metabolic pathway crucial in immune responses and inflammatory conditions including asthma
Mechanism: Alterations in AA LOX pathway, particularly imbalance between cysteinyl leukotrienes (pro-inflammatory) and lipoxin A4 (anti-inflammatory), impact asthma control
Clinical: CysLTs and LTB4 markedly elevated in asthmatic individuals vs. healthy controls; increase with asthma severity
29. Al-Shawwa BA, Al-Huniti NH, DeMattia L, Gershan W. (2015). "Adipokines and Cysteinyl Leukotrienes in the Pathogenesis of Asthma." Journal of Inflammation Research, 8: 173-180.
Key Finding: Leptin/adiponectin ratio higher in obese asthmatics vs. obese non-asthmatics; exhaled breath condensate cys-LT levels elevated in asthmatics
Mechanism: Proinflammatory adipokines from adipose tissue promote asthma phenotype through enhanced cys-LT (AA-derived) production
Implication: Links obesity-associated adipose tissue dysfunction to asthma severity
30. Magnusson J, Kull I, Rosenlund H, et al. (2017). "Polyunsaturated fatty acids linked to reduced allergy risk." Journal of Allergy and Clinical Immunology, 139(6): 1821-1829.
Key Finding: High blood levels of AA at age 8 associated with reduced risk of asthma and rhinitis at age 16
Notable: Among children with asthma/rhinitis at age 8, higher AA associated with higher probability of being symptom-free at age 16
Interpretation: Context-dependent effects of AA; may have protective effects in developing immune systems
31. Thien FCK, Hallsworth MP, Soh C, Lee TH. (2014). "Arachidonic acid intake and asthma risk in children and adults: a systematic review." British Journal of Nutrition, 112(3): 364-374.
Systematic Review: Eleven studies examined; mixed evidence on AA exposure and asthma risk
Conclusion: Cysteinyl leukotrienes derived from AA are important pro-inflammatory mediators in asthma pathogenesis
Alzheimer's Disease & Cognitive Decline
32. Abdullah L, Evans JE, Bishop A, et al. (2017). "APOE ε4 specific imbalance of arachidonic acid and docosahexaenoic acid in serum phospholipids identifies individuals with preclinical Mild Cognitive Impairment/Alzheimer's Disease." Aging, 9(3): 964-985.
Key Finding: APOE ε4-carriers converting to MCI/AD had high AA/DHA ratios in phospholipids vs. cognitively normal ε4 and non-ε4 carriers
Diagnostic Accuracy: AA and DHA containing PL species + ε4-status + Aβ42/Aβ40 ratios provided 91% accuracy detecting MCI/AD
Mechanism: Increased AA/DHA ratio promotes inflammation, contributing to AD pathogenesis; apoE4 impairs DHA transport to brain
Therapeutic Implication: Early DHA supplementation may prevent transition from normal aging to pathologic aging
33. Snowden SG, Ebshiana AA, Hye A, et al. (2017). "Fatty acid metabolism in the brain - Alzheimer disease." Frontiers in Neuroscience, 11: 20.
Key Finding: Unsaturated fatty acid metabolism significantly dysregulated in AD brains
Mechanism: AA metabolism produces pro-inflammatory lipid metabolites (prostaglandins, leukotrienes) vs. DHA generates anti-inflammatory mediators (resolvins)
34. Hennebelle M, Otoki Y, Yang J, et al. (2025). "Fatty acids and Alzheimer's Disease: Evidence on Cognition and Neurodegeneration." Journal of Prevention of Alzheimer's Disease, 12(1): 1-15.
Key Finding: Brain highly enriched in PUFAs; imbalance between AA (omega-6) and DHA (omega-3) associated with AD pathogenesis
Population Studies: Chicago Health and Aging study showed unsaturated fat negatively associated with AD risk
35. Blasbalg TL, Hibbeln JR, Ramsden CE, et al. (2011). "Country-level incidence of Alzheimer disease and related dementias is positively associated with omega-6 PUFA intake." Journal of Alzheimer's Disease, 25(4): 585-594.
Key Finding: Omega-6 PUFA intake exhibits positive linear relationship with age-standardized incidence rate of Alzheimer's disease
Implication: Population-level AA precursor (omega-6) intake correlates with AD incidence
Chronic Kidney Disease (CKD)
36. Yang T, Wu P, Liu L, et al. (2024). "Arachidonic acid metabolism as a therapeutic target in AKI-to-CKD transition." Frontiers in Pharmacology, 15: 1365802.
Key Finding: AA and eicosanoid derivatives play important roles in regulation of physiological kidney function and pathogenesis of kidney disease
Mechanism: AA metabolites drive inflammatory processes and oxidative stress in AKI progression to CKD
Clinical Features: DN characterized by proteinuria and progressive reduction in kidney function; inflammation and oxidative stress are major pathophysiological mechanisms
37. Navaneethan SD, Yehnert H, Moustarah F, et al. (2021). "Impact of adipose tissue in chronic kidney disease development." Current Opinion in Nephrology and Hypertension, 30(2): 197-206.
Key Finding: Excessive adipose tissue associated with inflammation, oxidative stress, insulin resistance, and RAAS activation
Mechanism: Adipocytes contribute up to 30% of circulating angiotensinogen; increased angiotensin II affects renal hemodynamics → hyperfiltration, glomerulomegaly, focal glomerulosclerosis
Leptin Connection: Elevated leptin from adipose tissue stimulates sympathetic nervous system, promotes renal sodium reabsorption, increases blood pressure, and induces renal scarring
38. Nowak JK, Walkowiak D, Nowak R. (2020). "Effect of renal replacement therapy on selected arachidonic acid derivatives in patients with chronic kidney disease." Scientific Reports, 10: 15092.
Key Finding: Type of renal replacement therapy significantly affects concentration of AA derivatives
Clinical Relevance: Platelet activation during dialysis results in release of AA from activated platelets; AA involved in pathogenesis of kidney disease including inflammation, hypertension, and diabetes
39. Hu X, Hu J, Li M, et al. (2020). "Recent Progress on Lipid Intake and Chronic Kidney Disease." Journal of Nutrition and Metabolism, 2020: 3680397.
Key Finding: Incidence of CKD associated with major abnormalities in circulating lipoproteins and renal lipid metabolism
Mechanism: Imbalance between lipid accumulation and disposal induces kidney damage
*40. Yeung SMH, Nogueira JP, Ouwens DM, et al. (2025). "Polyunsaturated fatty acids in kidney diseases: Navigating the fine line between benefits and risks." Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, 1870(3): 159587.**
Key Finding: PUFAs regulate renal inflammation through metabolites generated by COX, LOX, and CYP pathways
Complexity: Context-dependent effects; some AA metabolites protective, others harmful depending on enzymatic pathway and disease stage
Rheumatoid Arthritis (RA)
41. Navarini L, Margiotta DPE, Caso F, et al. (2004). "Do arachidonic acid and its metabolites, secreted by rheumatoid synovial cells, play a role in the pathogenesis of rheumatoid arthritis?" Joint Bone Spine, 71(5): 368-373.
Key Finding: AA metabolic pathway gives rise to prostaglandins (responsible for pain and swelling), leukotrienes, thromboxane, and HETEs involved in RA inflammatory situations
Mechanism: AA metabolites responsible for progressive destruction of cartilage and bone in RA
42. Löfvenmark I, Håkansson N, Gomez-Cabrero D, et al. (2018). "Do Fatty Acids Underlie Rheumatoid Arthritis Pathology?" PLOS ONE, 13(8): e0202607.
Key Finding: Patients with aggressive RA have altered non-esterified fatty acid profile including lower levels of AA (along with EPA and DHA), coinciding with enhanced Th1 response
Clinical Association: NEFA low profile associated with RF, shared epitope, erosions, and IFNγ expression in CD4+ T cells
Therapeutic Implication: Lower EPA and DHA at RA onset may make difficult to counteract Th1 responses → exacerbated inflammation
43. Veselinovic M, Vasiljevic D, Vucic V, et al. (2017). "Correlation of fatty acid composition of adipose tissue lipids and serum phospholipids with acutely inflamed synovial fluid in patients with rheumatoid arthritis." BMC Musculoskeletal Disorders, 18: 106.
Key Finding: RA patients had low concentrations of essential fatty acids (linoleic and linolenic) and high concentrations of total saturated fatty acids in both serum phosphatidylcholine and adipose tissue
Disease Duration: Abnormalities increased with disease duration
Mechanism: Decreases in essential fatty acids related to increased desaturase/elongation enzyme activity, increased eicosanoid production, or metabolic changes secondary to cytokine-mediated inflammatory reaction
44. Calder PC. (2012). "Influence of marine n-3 polyunsaturated fatty acids on immune function and response to rheumatoid arthritis." Proceedings of the Nutrition Society, 71(3): 348-362.
Key Finding: N-6 PUFA AA is precursor of inflammatory eicosanoids involved in RA; some RA therapies target AA metabolism
Mechanism: Marine n-3 PUFAs (EPA, DHA) decrease AA content of immune cells and decrease production of inflammatory eicosanoids from AA
45. Palle S, Vaghela B, Patil RH, et al. (2024). "Rheumatoid Arthritis and Omega-3 Fatty Acids: Decades of Studies Yield No Clear Answers." Rheumatology Advisor.
Mechanism: DHA and EPA are homologues with AA and can be used in same metabolism pathways regulating inflammation; their end products (eicosanoids) are less potent than those from AA → less inflammation and pain
Prevention Potential: People with anti-cyclic citrullinated peptide autoantibodies had lower EPA and DHA; omega-3 FAs may help prevent development of autoimmunity and RA
Summary Statistics
This compilation includes 45 peer-reviewed research papers demonstrating associations between higher adipose tissue arachidonic acid levels and the following chronic disease conditions:
Metabolic Syndrome (1 study)
Cardiovascular Disease/Myocardial Infarction (6 studies)
Obesity & Adipose Inflammation (4 studies)
Type 2 Diabetes & Insulin Resistance (3 studies)
Non-Alcoholic Fatty Liver Disease (6 studies)
Hypertension (3 studies)
Cancer (Prostate & Breast) (5 studies)
Asthma & Allergic Disease (4 studies)
Alzheimer's Disease & Cognitive Decline (4 studies)
Chronic Kidney Disease (4 studies)
Rheumatoid Arthritis (5 studies)
Key Mechanistic Themes
Pro-inflammatory Eicosanoid Production: AA serves as precursor for prostaglandins, leukotrienes, and thromboxanes that drive chronic inflammation
Metabolic Independence from Diet: Multiple studies show adipose tissue AA levels not correlated with dietary AA or LA intake, suggesting endogenous metabolic regulation
Dose-Response Relationships: Several studies demonstrate graded risk increases across quintiles of adipose tissue AA
Tissue-Specific Effects: AA in adipose tissue may have different effects than AA in muscle, plasma, or erythrocytes
Interaction with APOE Genotype: In Alzheimer's disease, AA/DHA ratios particularly harmful in APOE ε4 carriers
Comments
Post a Comment